Effect of Clarithromycin on the Pharmacokinetics of Cabergoline in Healthy Controls and in Patients With Parkinson's Disease

• Hauptverfasser: Akiko Nakatsuka (Verfasst von), Masahiro Nagai (Verfasst von), Hayato Yabe (Verfasst von), Noriko Nishikawa (Verfasst von), Takuo Nomura (Verfasst von), Hiroyoko Moritoyo (Verfasst von), Takashi Moritoyo (Verfasst von), Masahiro Nomoto (Verfasst von)
• Format: Buch
• Veröffentlicht: Elsevier, 2006-01-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract.: Cabergoline is used in the treatment of Parkinson's disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often co-administered with cabergoline in usual clinical practice. We studied the effect of clarithromycin co-administration on the blood concent...